olopatadine hydrochloride and mometasone furoate monohydrate (Ryaltris)

following an abbreviated submission:

olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) is accepted for restricted use within NHSScotland.

Indication under review: in adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis.

SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Olopatadine hydrochloride / mometasone furoate monohydrate (Ryaltris®) offers an additional treatment choice of antihistamine and glucocorticoid in a single nasal spray. SMC has previously accepted an alternative antihistamine / glucocorticoid combination for use in allergic rhinitis.

For patients in whom the combination of olopatadine hydrochloride plus mometasone furoate monohydrate is an appropriate choice of therapy, Ryaltris® provides the two ingredients in a single nasal spray.

​